FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3169602208> ?p ?o ?g. }

• W3169602208 endingPage "e19040" @default.
• W3169602208 startingPage "e19040" @default.
• W3169602208 abstract "e19040 Background: Clinical trials investigating JAK1/JAK2 inhibitors for myelofibrosis (MF) subjects have measured symptom improvement as a minimum 50% reduction in total symptom score (TSS) at the end of a 24-week treatment period. This landmark analysis is based on post-baseline score changes from Weeks 21 (W21) to 24 and requires vastly different absolute TSS improvements for patients with very high or low baseline (BL) TSS to reach responder status. A phase 3 clinical study, SIMPLIFY-1, randomized 432 intermediate and high risk JAK inhibitor (JAKi) naive MF patients 1:1 to momelotinib (MMB) or ruxolitinib (RUX). Non-inferiority on the MPN-SAF TSS response rate endpoint at W24 was not met (MMB: 28% vs RUX: 42%); however, improvement in each of the 7 TSS items was similar for MMB vs RUX. To understand the discrepancy, we applied item analysis and mixed effect models for repeated measures (MMRM) to SIMPLIFY-1. Methods: Analyses were conducted in the intention-to-treat (ITT) population and in a symptomatic subset (selected as subjects with BL TSS ≥ 10). The distributions of TSS items were examined at BL and shift in scores at W24 (health state shifts) were assessed. GEE models were used to estimate item-level odds ratios using multiple predictive imputations for missing data. MMRM compared mean change in TSS from BL to W24 using data from all visits. The meaningful change threshold (MCT) was determined using Patient Global Impression of Change. Results: BL scores across items were heterogenous in the MMB and RUX groups; the proportion of subjects with no or mild symptoms (0–3 on a 0-10 point scale) ranged from 44% (tiredness) to 81% (itching). Distributions of BL scores were different across arms with 6 out of 7 items in the MMB arm reporting more severe or very severe symptoms (scores of 7-10) at BL. Despite the imbalance in BL scores, item-level health state shifts showed similar improvements for MMB and RUX. Categorical responder analysis showed no significant differences on any items. Odds ratios for each between-group comparison ranged from 0.74 to 1.20. MMRM mean TSS change at W24 was 6.35 (MMB) vs 7.87 (RUX) in the ITT and 8.80 (MMB) vs 10.46 (RUX) in the symptomatic subset. Mean TSS were near the within-subject MCT of 8 points in the ITT and exceeded the MCT in the symptomatic subset. The between-group difference was 1.52 (95% CI: (0.196, 2.847)) in the ITT and 1.67 (95% CI: -0.134, 3.468) in the symptomatic subset. Conclusions: Comparable item health state shifts at W24 and similar improvements in mean TSS as shown by MMRM, with a minimal between-group difference of 1.52 on the 70 point scale in context of an 8-point MCT suggest MMB provides clinically relevant and comparable symptom improvements to RUX; these analyses require further validation in independent data sets. Imbalance in BL symptom scores in MMB subjects may have contributed to the inability to demonstrate non-inferiority in TSS response rate at W24. Clinical trial information: NCT01969838." @default.
• W3169602208 created "2021-06-22" @default.
• W3169602208 creator A5002632381 @default.
• W3169602208 creator A5002761999 @default.
• W3169602208 creator A5006447658 @default.
• W3169602208 creator A5008609620 @default.
• W3169602208 creator A5017537622 @default.
• W3169602208 creator A5025797543 @default.
• W3169602208 creator A5039057642 @default.
• W3169602208 creator A5039934076 @default.
• W3169602208 creator A5047899373 @default.
• W3169602208 creator A5053710126 @default.
• W3169602208 creator A5057941081 @default.
• W3169602208 creator A5061769066 @default.
• W3169602208 creator A5066614305 @default.
• W3169602208 creator A5067214379 @default.
• W3169602208 creator A5072839097 @default.
• W3169602208 creator A5074647388 @default.
• W3169602208 creator A5079124367 @default.
• W3169602208 creator A5080593577 @default.
• W3169602208 creator A5084322798 @default.
• W3169602208 creator A5085521139 @default.
• W3169602208 date "2021-05-20" @default.
• W3169602208 modified "2023-09-23" @default.
• W3169602208 title "Longitudinal and individual symptom analyses of momelotinib and ruxolitinib treated myelofibrosis patients from SIMPLIFY-1." @default.
• W3169602208 doi "https://doi.org/10.1200/jco.2021.39.15_suppl.e19040" @default.
• W3169602208 hasPublicationYear "2021" @default.
• W3169602208 type Work @default.
• W3169602208 sameAs 3169602208 @default.
• W3169602208 citedByCount "0" @default.
• W3169602208 crossrefType "journal-article" @default.
• W3169602208 hasAuthorship W3169602208A5002632381 @default.
• W3169602208 hasAuthorship W3169602208A5002761999 @default.
• W3169602208 hasAuthorship W3169602208A5006447658 @default.
• W3169602208 hasAuthorship W3169602208A5008609620 @default.
• W3169602208 hasAuthorship W3169602208A5017537622 @default.
• W3169602208 hasAuthorship W3169602208A5025797543 @default.
• W3169602208 hasAuthorship W3169602208A5039057642 @default.
• W3169602208 hasAuthorship W3169602208A5039934076 @default.
• W3169602208 hasAuthorship W3169602208A5047899373 @default.
• W3169602208 hasAuthorship W3169602208A5053710126 @default.
• W3169602208 hasAuthorship W3169602208A5057941081 @default.
• W3169602208 hasAuthorship W3169602208A5061769066 @default.
• W3169602208 hasAuthorship W3169602208A5066614305 @default.
• W3169602208 hasAuthorship W3169602208A5067214379 @default.
• W3169602208 hasAuthorship W3169602208A5072839097 @default.
• W3169602208 hasAuthorship W3169602208A5074647388 @default.
• W3169602208 hasAuthorship W3169602208A5079124367 @default.
• W3169602208 hasAuthorship W3169602208A5080593577 @default.
• W3169602208 hasAuthorship W3169602208A5084322798 @default.
• W3169602208 hasAuthorship W3169602208A5085521139 @default.
• W3169602208 hasConcept C102959455 @default.
• W3169602208 hasConcept C105795698 @default.
• W3169602208 hasConcept C126322002 @default.
• W3169602208 hasConcept C203092338 @default.
• W3169602208 hasConcept C27403532 @default.
• W3169602208 hasConcept C2776112149 @default.
• W3169602208 hasConcept C2780007613 @default.
• W3169602208 hasConcept C2780076729 @default.
• W3169602208 hasConcept C2908647359 @default.
• W3169602208 hasConcept C33923547 @default.
• W3169602208 hasConcept C53084192 @default.
• W3169602208 hasConcept C535046627 @default.
• W3169602208 hasConcept C71924100 @default.
• W3169602208 hasConcept C99454951 @default.
• W3169602208 hasConceptScore W3169602208C102959455 @default.
• W3169602208 hasConceptScore W3169602208C105795698 @default.
• W3169602208 hasConceptScore W3169602208C126322002 @default.
• W3169602208 hasConceptScore W3169602208C203092338 @default.
• W3169602208 hasConceptScore W3169602208C27403532 @default.
• W3169602208 hasConceptScore W3169602208C2776112149 @default.
• W3169602208 hasConceptScore W3169602208C2780007613 @default.
• W3169602208 hasConceptScore W3169602208C2780076729 @default.
• W3169602208 hasConceptScore W3169602208C2908647359 @default.
• W3169602208 hasConceptScore W3169602208C33923547 @default.
• W3169602208 hasConceptScore W3169602208C53084192 @default.
• W3169602208 hasConceptScore W3169602208C535046627 @default.
• W3169602208 hasConceptScore W3169602208C71924100 @default.
• W3169602208 hasConceptScore W3169602208C99454951 @default.
• W3169602208 hasIssue "15_suppl" @default.
• W3169602208 hasLocation W31696022081 @default.
• W3169602208 hasOpenAccess W3169602208 @default.
• W3169602208 hasPrimaryLocation W31696022081 @default.
• W3169602208 hasRelatedWork W1753898346 @default.
• W3169602208 hasRelatedWork W2047079934 @default.
• W3169602208 hasRelatedWork W2117215550 @default.
• W3169602208 hasRelatedWork W2275243588 @default.
• W3169602208 hasRelatedWork W2363926121 @default.
• W3169602208 hasRelatedWork W2609535710 @default.
• W3169602208 hasRelatedWork W3169602208 @default.
• W3169602208 hasRelatedWork W4295903721 @default.
• W3169602208 hasRelatedWork W4296530176 @default.
• W3169602208 hasRelatedWork W2810368072 @default.
• W3169602208 hasVolume "39" @default.
• W3169602208 isParatext "false" @default.
• W3169602208 isRetracted "false" @default.
• W3169602208 magId "3169602208" @default.
• W3169602208 workType "article" @default.